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Summary
Statistical methods for survival analysis play a central role in the assessment of treatment effects
in randomized clinical trials in cardiovascular disease, cancer, and many other fields. The most
common approach to analysis involves fitting a Cox regression model including a treatment indi-
cator, and basing inference on the large sample properties of the regression coefficient estimator.
Despite the fact that treatment assignment is randomized, the hazard ratio is not a quantity which
admits a causal interpretation in the case of unmodelled heterogeneity. This problem arises be-
cause the risk sets beyond the first event time are comprised of the subset of individuals who have
not previously failed. The balance in the distribution of potential confounders between treatment
arms is lost by this implicit conditioning, whether or not censoring is present. Thus while the Cox
model may be used as a basis for valid tests of the null hypotheses of no treatment effect if robust
variance estimates are used, modeling frameworks more compatible with causal reasoning may
be preferable in general for estimation.
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1 INTRODUCTION
Kaplan-Meier estimation (Kaplan and Meier, 1958) and Cox regression models (Cox, 1972) play a
central role in the assessment of treatment effects in randomized clinical trials of cardiovascular dis-
ease, cancer and many other medical fields. When interest lies in delaying the time to an undesirable
event, both methods naturally accommodate right censoring. The Cox regression model, however,
is particularly appealing because it yields a simple summary of the treatment effect in terms of the
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hazard ratio, which can be interpreted as a type of relative risk. The semiparametric nature of the
model, the ability to stratify in multi-center trials, and the connection with the log-rank test have also
contributed to its widespread use.
Randomization is usually viewed as the ideal approach for eliminating the effects of confounding
variables to ensure causal inferences can be drawn. In randomized clinical trials with a survival
outcome, it is customary to express treatment effects by estimates of the hazard ratio often without
adjusting for even known prognostic variables. When viewing Cox regression from a causal point of
view, omission of these terms creates problems which do not seem to be widely appreciated in some
fields.
First we would like to point out that several limitations of the Cox model are well known. The
selection effects well documented in frailty theory (e.g. Aalen et al., 2008), constitute one example
to be mentioned below. A related issue is the fact that Cox models which condition on different
sets of covariates cannot simultaneously be valid (Ford et al., 1995). Our intent is to focus on the
limitations of the Cox model from a causal point of view, some of which have been pointed out in the
epidemiological literature (Greenland, 1996, Herna´n, 2010, Herna´n et al., 2004; Herna´n and Robins,
2015, Section 8.3). Our paper is partly a review of these ideas, but we discuss this in a broader setting
and wish to present the issues to a biostatistical audience concerned with survival analysis.
The basic notion may be explained intuitively as follows: for a randomized study of survival
times the first contribution to the Cox partial likelihood is based on a randomized comparison, but
subsequent partial likelihood contributions are based on biased comparisons. This bias arises when
there are known or unknown factors influencing survival which are not controlled for in the analysis;
we believe this is almost always the case.
Our aims are to further clarify these issues through a simple mathematical argument and to provide
further discussion, including the relationship to frailty theory. Cox regression is used routinely in
clinical trials for the analysis of time to event response. We suggest that analysts applying these
methods take it for granted that the hazard ratio gives a valid representation of the causal effect. It
is therefore important to realize the limitations of this analysis. We focus here on settings where the
goal is to assess the effect of treatment versus a control intervention on the time to an event in the
context of a randomized clinical trial.
The theory of counting processes plays a fundamental role in survival and event history analysis.
The probabilistic structure of counting processes is defined in terms of intensity processes. If N(t)
is the process counting events over time (e.g. occurrences of undesirable clinical events), then the
intensity process is :
λ(t;H(t)) = lim
∆→0
1
∆
P (N(t+ ∆)−N(t) = 1|H(t)) (1)
where H(t) is the history of the event process observed up to time t; we assume that the information
from the past grows as t increases. In words, the intensity process gives the probability of an event
occurring in a small time interval [t, t + ∆) given the past history observed to an instant before t. A
precise mathematical treatment requires tools from martingale theory (Aalen et al., 2008).
The intensity process is based on the concept of prediction in that it involves the exploitation of
information unfolding over time in order to model the instantaneous risk of an event. The utility of
intensity-based modeling is clear in settings where interest lies in understanding dynamic features of
a complex event process and associated risk factors. An important question in the setting of a clinical
trial, however, is whether the event intensity can also be given a structural, or causal interpretation.
Generally, of course, one cannot expect a structural interpretation due to unmeasured confounders or
other issues.
Pearl (2009) gives a careful discussion of the requirements for a model to admit causal inferences
and introduces the important tool of the do-operator. In the present context a causal statement can be
made with respect to a particular intervention E if
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λ(t|H(t), e) = λ(t|H(t), do(e)) (2)
where do(e) means that the value of E is set to e by an external manipulation. The intervention E
may correspond to changing an element in the history of the process, and the intensity process clearly
does not tell you what the result of that would be unless (2) is fulfilled.
In the analysis presented here, the concepts of collider effect and controlled direct effect also play
a central role, and we shall follow the ideas of Pearl (2009) here as well. In a process setting one has
to show some care in applying these ideas (Aalen et al., 2014).
2 RANDOMIZED COMPARISON OF TREATMENTS IN SURVIVAL ANALYSIS
2.1 CONFOUNDING AMONG SURVIVORS
The risk of an event may vary considerably between individuals under study due to known and un-
known factors. Examples of known factors might be the duration and stage of the disease at the time
of recruitment, smoking status, and so on. Other features such as dietary history, level of physical
activity, and environmental exposures are more difficult to measure and are typically not recorded.
Genetic and epigenetic features are likely to have strong effects. We consider and represent these var-
ious influential factors collectively in a variable Z. Note that this variable is not routinely considered
to have a confounding effect per se in a clinical trial with randomization, since randomization ensures
Z ⊥⊥ X at the time of treatment assignment. Randomization does not, however, eliminate the effect
of this variable on the outcome and as a consequence does not ensure the same independence among
individuals surviving to any time t > 0, i.e. we do not necessarily have Z ⊥⊥ X|T > t.
To expand on this, we assume that the hazard rate for an individual in a population of interest is
given as h(t,X, Z). Here X is a treatment indicator and Z is the variable that contains individual
specfic quantities that influence survival. If the treatment assignment is randomized at t = 0, X and
Z are stochastically independent at that time. For simplicity, we shall assume here that X and Z are
discrete, but a similar argument would of course hold for continuous variables. The joint distribution
of X and Z for survivors to time t is given by:
P (Z = z,X = x|T ≥ t) = P (Z = z,X = x, T ≥ t)
P (T ≥ t)
=
P (T ≥ t|Z = z,X = x)P (Z = z,X = x)
P (T ≥ t)
=
exp(− ∫ t
0
h(s, x, z)ds)P (Z = z)P (X = x)
P (T ≥ t) . (3)
This expression can only be factored with respect to the two covariates for all t if h(t, x, z) is
additive in the following sense:
h(t, x, z) = a(t, x) + b(t, z) (4)
If this is not the case, then it is apparent from (3) that X and Z are not independent among the
survivors (i.e. given T ≥ t).
Note that the hazard of the Cox model does not satisfy the additivity assumption in equation (4).
This is also the case for a marginal Cox model containing only the covariate X: if the joint hazard in
X and Z satisfies (4) then the marginal model for X would retain an additive component and would
not be of the Cox form.
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The lack of independence between X and Z among the survivors to time t has an important im-
plication for the Cox model since the partial likelihood is built up by considering contributions which
condition on survival to increasingly large times. Despite randomization at t = 0, the contributions to
the Cox partial likelihood following the first failure will not be in a randomized setting. This makes
it unclear what the hazard ratio computed for a randomized survival study really means. Note, that
this has nothing to do with the fit of the Cox model. The model may fit perfectly in the marginal case
with X as the only covariate, but the present problem remains.
The effect we are discussing depends on the probability of surviving; as shown in (3). If the event
in question is rare, then the effect will be small.
2.2 AN ILLUSTRATIVE CALCULATION
SupposeX and Z are binary 0−1 variables with P (Z = 1) = pi and whereX is assigned by balanced
randomized with P (X = 1) = 0.5. Under a Weibull proportional hazards model we define H0(t) =
(h0t)
κ and consider the survivor functions P (T ≥ t|X,Z) = exp(−H0(t) exp(β1X +β2Z)), P (T ≥
t|X) = EZ{exp(−H0(t) exp(β1X + β2Z))}, and P (T ≥ t) = EX [EZ{exp(−H0(t) exp(β1X +
β2Z))}]. We set h0 = 1 and κ = 1 and consider β1 = log 0.5 to correspond to a strong treatment
effect and β2 = log 4 to reflect a highly influential risk factor. We consider the pth percentile Qp, of
the marginal survival distribution, satisfying 1 − p = P (T > Qp), with p = 0, 0.10, 0.25, 0.50, 0.75
and 0.90. In Figure 1 we display P (Z = 1|X,T ≥ Qp) from study entry for the case of common
risk factor (pi = 0.50). There is a striking imbalance in the risk factor evident in the second and
third quartiles of T . Evidence of treatment effect from individuals at risk at this time is therefore
heavily influenced by this risk factor. The light grey line reflects the log odds ratio characterizing the
association between Z and X given T > Qp, clearly conveying the evolving dependence between
treatment and the risk factor.
The Weibull proportional hazards model is the only parametric model which can be reformulated
as a location-scale model (Cox and Oakes, 1984). We can therefore write it equivalently as
Y = γ0 + γ1X + γ2Z + τW
where Y = log T , τ = κ−1 is a dispersion parameter, and W ⊥⊥ (X,Z) has a standard extreme value
error distribution; note also that γj = −τβj , j = 1, 2 and γ0 = − log h0. While we may think of this
model as operating in the population of interest, when the treatment assignment is randomized in a
clinical trial, we aim to estimate features of the distribution of T |X . The effect of interest is contained
in the systematic part of the model for Y |X ,
E(Y |X) = γ0 + γ1X + γ2E(Z|X) + τE(W |X) = γ∗0 + γ1X .
As a consequence, the effect of treatment in the location scale formulation, or its alternative utilization
in terms of an accelerated failure time model (Wei, 1992), does yield a causal measure of treatment
effect. The collapsibilities of this model and the causal interpretation have lead to the widespread
use of accelerated failure time models in causal inference (e.g. Robins, 1992). Consistent estimation
of γ1 based on the model for T |X will require correct specification of the error distribution, but
estimation of the coefficients in the location scale formulation is quite robust to misspecification of the
error distribution (Gould and Lawless, 1988; Lawless, 2003, Section 6.3.4) and fitting semiparametric
versions of this model can provide robust estimation under some forms of censoring.
We consider a brief simulation study to illustrate the utility of the location-scale model in this
setting. We consider pi = 0.10 and 0.50 whereX is determined by randomization; so P (X = 1) = 0.5
and X ⊥⊥ Z. An administrative censoring time C† was set such that P (T > C†) = 0.10 and an
exponential random censoring time accommodated early withdrawal with rate ρ selected to give a net
censoring rate of 30% or 50% respectively. Analyses were carried out based on Cox regression and
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a semiparametric accelerated failure time model using the method of Brown and Wang (2005): point
estimates and robust variance estimates were recorded for each simulated sample.
With κ = 1, the regression coefficient in the accelerated failure time model is simply the negative
of the coefficient in the Cox model and the empirical biases and coverage probabilities are evaluated
relative to the respective true values.
Table 1: Empirical properties of estimators obtained by fitting marginal Cox and semiparametric
accelerated failure time models for T |X when the correct model is a Weibull proportional haz-
ards/accelerated failure time model for T |X,Z; P (Z = 1) = pi, 10% administrative censoring
and CEN% reflects net censoring incorporating random withdrawal, 500 individuals per dataset;
nsim=2000
Cox Model AFT Model
pi CEN% EBIAS ESE RSE ECP% EBIAS ESE RSE ECP%
0.1 30 0.043 0.111 0.109 92.2 0.003 0.135 0.131 94.5
50 0.048 0.129 0.130 92.6 0.004 0.161 0.157 94.3
0.5 30 0.147 0.108 0.108 72.9 0.001 0.146 0.142 93.8
50 0.120 0.131 0.129 84.3 0.002 0.169 0.163 93.8
EBIAS is mean estimate minus β1 (Cox) and γ1 (AFT) respectively, ESE is the empirical standard error, RSE
is the mean robust standard error, and ECP% is the empirical coverage probability
The bias evident in the estimation of β1 from the Cox model arises because it is not collapsible
and is sensitive to the distribution of the prognostic factor as well as the censoring distribution; this
is the case with misspecified Cox models generally, for which the large sample properties of associ-
ated estimators are now well known (Struthers and Kalbfleisch, 1986). Hypothesis tests directed at
detecting treatment effects are valid in such settings, however, provided robust variance estimates are
used (Lin and Wei, 1989). The empirical biases in the estimators of the coefficients in the accelerated
failure time model are negligible in all cases and so are insensitive to the distribution of the covariate
and censoring rates, and there is generally close agreement between the empirical and mean robust
standard errors.
3 INTERPRETATION IN A CAUSAL INFERENCE SETTING
The concept of a collider is used to clarify the effects of selection bias in causal reasoning. A collider
is present in a directed acyclic graph (DAG) if two arrows meet at a node. When conditioning on
a collider the effects may “pass through” the collider, and since it does not exert a causal effect, a
bias may be induced in the estimate of the effect of the intervention. See Pearl (2009) for a general
introduction to these matters.
Consider two times, t and t + ∆ where ∆ > 0, and let St and St+∆ indicate survival up to these
times respectively. A model for the causal structure of this situation is shown in the directed acyclic
graph of Figure 2.
If we consider the comparison of treatments with respect to St or St+∆ separately, then a random
allocation will ensure a valid assessment of the causal effect. For instance, when considering the
effect of X on St+∆, the noncausal path, via Z, is closed as long as we do not condition on St. The
node St is a collider and closes the path via Z as long as it is not conditioned upon.
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Z(Variable influencing survival)
'' $$
St //(Survived up to t) St+∆ (Survived up to t+ ∆)
X(Treatment)
77 ::
Figure 2: A directed acyclic graph of X , Z and St and St+∆
If, however, we consider the probability of surviving up to time t + ∆, conditional on survival
up to time t, then the situation is changed. This change arises because we condition on a collider St,
which activates the noncausal path X → St ←− Z → St+∆. If Z is (in whole or partially) unknown,
this path cannot be closed. This implies that we generally have X 6⊥⊥ Z | T > t, so the compositions
of the groups of treated and non-treated survivors at time t differ systematically, even if the treatment
was randomly assigned at t = 0. This is a problem if we wish to assign meaning to differences of the
respective hazard rates at time t since the hazards at time t are sensitive to previous survival in the
two groups.
It is not automatically the case that conditioning on colliders breaks the randomization, and to
clarify the conditions for this, our argument has to be supplied with a calculation as is done in Section
2.1. If the additivity condition in equation (4) is fulfilled, then we do indeed have X ⊥⊥ Z | T > t, so
the randomization will not be broken by restricting to survivors at t.
In order to assess short-term treatment effects, not as sensitive to such systematically diverging
group compositions, we imagine a hypothetical variant of our initial trial. Whenever an individual
dies before t, we replace him by an identical individual that is still alive, and do not record the death
that occurred before t. Then we compare the risk of deaths during (t, t + ∆] for the treated vs. the
non-treated individuals. This would provide a comparison of short-term treatment effects at time t,
not sensitive to selection effects due to previous deaths, since the groups are identical to those that
where formed by randomization at baseline.
In terms of causal inference, this corresponds to what is known as the controlled direct effect of
treatment (Pearl, 2009), and equals:
θx(t) = lim
∆→0
∆−1 · P (St+∆ = 0 | do(X = x, St = 1))
= lim
∆→0
∆−1 ·
∫
z
P (St+∆ = 0 | X = x, St = 1, z)P (dz),
where the last expression follows from Pearl (2009, equation (3.19)). The open path St ← Z → St+∆
means that we generally have that P (St+∆ = 0 | do(x, St = 1)) 6= P (St+∆ = 0 | X = x, St = 1), so
our comparison can not be carried out by a straight-forward regression analysis among the survivors
at time t. This has also been pointed out by Herna´n et al. (2004) and Herna´n and Robins (2015).
One could also take another point of view where instead of considering the controlled direct effect
we consider the causal effect of treatment on short term survival conditionally on Z. By conditioning
we achieve that the causal effect of treatment shall correspond to the effect it has on an individual
with a given value Z = z. Let the hazard rates for an individual with Z = z be as follows under the
control (X = 0) and experimental treatment (X = 1) conditions respectively:
β0(t) = z α(t) , β1(t) = z rα(t) , (5)
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Hence, with the active treatment the individual will have r times the risk that he would have in the
control group. The relationship to the previous formulation is that the treatment X has two possible
options, and that for each individual the hazard is r times as large for one treatment option as for the
other.
Note that the conditioning with respect to Z closes the collider path X → St ←− Z → St+∆ in
Figure 2. The path X → St → St+∆ is already closed because we condition with respect to survival
at time t. Using (5) we can calculate the controlled direct effect as follows:
θx(t) =
∫
z
lim
∆→0
∆−1 · P (St+∆ = 0|X = x, St = 1, z)P (dz)
=
∫
z
zrxα(t)P (dz) = E(Z)rxα(t)
Thus we get that the controlled direct effect equals θ1(t)/θ0(t) = r.
We can also calculate the other causal parameter, i.e. the one conditional on Z. To identify this,
note that λ(t|do(x), z) = λ(t|x, z) where λ(t|·) denotes the intensity of an event given various pieces
of information. Hence we have from (5):
λ(t|do(X = 1), Z)
λ(t|do(X = 0), Z) =
λ(t|X = 1, Z)
λ(t|X = 0, Z) =
Z rα(t)
Z α(t)
= r.
Hence, the causal hazard ratios defined by the controlled direct effect of treatment or by the
conditional treatment effect given Z are both equal to r in this particular setting. This is not what is
estimated by a Cox model in the presence of random variation in Z.
4 CAUSALITY AND FRAILTY
Consider the counterfactual model (5) which, while similar in form to a standard frailty model, we
specify here as a basis for causal reasoning. In (5) we conceptualize the individual hazard rates under
both treatment schemes and define the causal effect of treatment in terms of these. In practice, of
course, a person will normally be assigned to one treatment, making the other assignment counterfac-
tual. In the counterfactual framework this means that (5) holds for any value of Z that an individual
might have. In randomized trials, however, we do not typically adjust for covariates on the presump-
tion that randomization has distributed them (more or less) equally between the treatment groups.
This corresponds to basing comparisons on the population average (marginal) survival distributions,
obtained after having implicitly averaged over Z; the effect of treatment at the individual level is not
specified.
The difficulty in assigning a causal interpretation to treatment effects can be related to known
phenomenon arising in frailty theory where it is well known that for certain types of frailty distribu-
tions (e.g. the compound Poisson distributions with positive probability of a zero frailty), population
(marginal) hazard functions may cross over purely as an artefact of unexplained heterogeneity in the
population (Flanders and Klein, 2007, Aalen et al., 2008). Hence even when a treatment is highly
effective in lowering the hazard at the individual level, at some time the instantaneous risk at the pop-
ulation level becomes higher in the treatment group than the control group. This phenomenon arises
in spite of the fact that for each value of the frailty variable (and hence for each individual) there is a
common and constant multiplicative effect of treatment on the hazard. A test statistic reflecting the
difference between treatment groups based on hazard rates (e.g. the logrank test) would therefore
increase as follow-up increases to a certain point and then decrease. Although there is a mathemati-
cal connection to frailty theory, the causal reasoning we put forward here gives new insight into the
concept of frailty and the phenomena that have been studied in this setting.
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Figure 3: Two gamma distributions with shape parameter 2 and scale parameters 3 and 4 respectively,
corresponding to the density of Z among survivors at time t with δ = 1, A(t) = 2 and with a causal
effect r = 1.5 as specified in equation (5)
To illustrate this point further, assume that Z is gamma distributed with expectation 1 (without
loss of generality) and variance δ. Corresponding to the model in (5), the population hazard rates
obtained by integrating out Z are given for the two treatment groups as follows:
µ0(t) =
α(t)
1 + δA(t)
, µ1(t) =
rα(t)
1 + δrA(t)
(6)
where A(t)=
∫ t
0
α(s)ds. These are standard formulas, see e.g. Aalen et al. (2008). Note, that in our
terminology µ0(t) = λ(t|X = 0) and µ1(t) = λ(t|X = 1).
The ratio of the two population hazard rates is:
R(t) =
µ1(t)
µ0(t)
= r ·
(
1 + δ A(t)
1 + rδ A(t)
)
. (7)
This hazard ratio converges towards 1 in contrast to the constant causal hazard ratio r for the coun-
terfactual model. The trend in R(t) is due to increasingly different distributions of Z for survivors
in the two groups. Figure 3 contains an illustrative plot of the gamma density of Z among survivors
at time t where each individual survival time has a cumulative hazard of A(t) or rA(t); the condi-
tional densities have the same shape parameter 1/δ and scale parameters 1/δ + A(t) or 1/δ + rA(t)
respectively.
In this setting we consider treatment effects that are not subject to selection due to frailty. To sum
up previous results, we have:
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θ1(t)
θ0(t)
= r =
λ(t|do(X = 1), Z)
λ(t|do(X = 0), Z) =
λ(t|X = 1, Z)
λ(t|X = 0, Z) 6=
λ(t|X = 1)
λ(t|X = 0) = r ·
(
1 + δ A(t)
1 + rδ A(t)
)
In a randomized trial when fitting a marginal model with just the treatment as a covariate, what
one estimates in a Cox model is not this causal quantity r, but a weighted average of R(t) (Lin and
Wei, 1989). This will typically be closer to 1.
Can one adjust for covariates to resolve this issue? Some have advocated that baseline covariates
should be controlled for in randomized trials (Hauck et al., 1998) but there is considerable discussion
and debate about if, when, and how this should be carried out. The point is that the information in Z
will at best only be partially known. There will with necessity be a number of dissimilarities between
individuals which are unknown and even unobservable. This is the issue of frailty theory. So, in
general the quantity r is not really estimable even from a randomized study.
We illustrate this by a small simulation without censoring. Assume there are two treatment groups
with 1000 individuals in each group. Conditional onZ the hazard rate isZ and 2Z in the two treatment
groups. Assume that Z is gamma distributed with scale parameter 1 and shape parameter a. In this
case the individual hazard ratio is r = 2. Using a Cox model the estimated hazard ratio is 1.04
when δ = 0.1 (extremely skewed Z), while it is is 1.36 when δ = 1 (exponential distribution for Z).
Hence, we do not get the correct individual hazard rate, but something that is strongly influenced by
the general variation in risk among individuals.
Finally, in order to emphasize the importance of interventions, we examine the issue of treatment
switching, discussed briefly in Aalen et al. (2008). We shall show how the effect of interventions
after time 0 are misrepresented in the statistical model disregarding the frailty, and that a causal
understanding is necessary. For that purpose we again use a gamma frailty model. Imagine that at
some time we intervene and switch the treatment group back to the control treatment. For instance,
one might observe that the hazard in two groups become very similar at some time and might wonder
whether there is still a point in giving the experimental treatment. We assume that switching the
treatment has an immediate effect at the individual level, meaning that the hazard for the treatment
group, conditional on Z, changes from Z rα(t) to Z α(t) at some time t1. Thus up to t1 the two
population (marginal) hazards are given in formula (6), but after t1 the population hazard rate for
group 1 is:
µ1(t) =
α(t)
1 + rδ A(t1) + δ(A(t)− A(t1)) , t > t1
The relative population hazard for t > t1 is:
µ1(t)
µ0(t)
=
1 + δ A(t)
1 + rδ A(t1) + δ(A(t)− A(t1))
= 1 + (1− r) δ A(t1)
1 + rδ A(t1) + δ(A(t)− A(t1)) .
This should be compared to the relative population hazard for t ≤ t1, which is R(t). So,
µ1(t)
µ0(t)
= r
1 + δ A(t)
1 + r δ A(t)
= 1− (1− r) 1
1 + r δ A(t)
.
for t ≤ t1.
Assuming r < 1, it follows that µ1(t)/µ0(t) is smaller than 1 before time t1 and larger than 1
afterwards, with a jump at t1. Hence, the treatment group will suddenly have a higher population
(marginal) hazard than the control group when treatment is discontinued, which means that the causal
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Figure 4: Hazard ratio when intervention is switched back to control at time 2.
effect of changing treatment cannot be discerned from the observed hazard rates prior to intervention.
The result is illustrated in Figure 4 where t1 = 2, α(t) = 1, r = 0.5 and δ = 2. The treatment
is switched back to control when the hazard ratio is close to 1 indicating no great difference in risk
between the two groups, but the result of the intervention is a surprising and large jump.
Causality is about understanding the effect of interventions. This example shows that the popula-
tion hazard rates do not necessarily give this causal insight, and that a correct causal understanding is
challenging.
5 DISCUSSION
A central point of this note is that the hazard ratio in a Cox regression model is not the natural causal
quantity to consider. This has been discussed by Greenland (1996), Herna´n (2010), and Herna´n et al.
(2004), among others, but it does not seem widely appreciated. In light of the structural problems
present with only fixed baseline variables, the current focus on the use of accelerated failure time
models (Wei, 1992), models based on time-transformations (Cheng et al., 1995, Lin et al., 2014), and
additive hazards models (Aalen, 1989) may be more appropriate.
In causal inference we do not presume there to be no confounding variables, but rather that they
are suitably dealt with in analysis in order to mitigate their effects. Randomization achieves this goal
in many settings by rendering the known and unknown confounding variables independent of the
treatment indicator. With the linear model this is sufficient to ensure that the model including only the
treatment indicator yields an estimator consistent for the marginal causal effect and one can likewise
define the effect of interest for binary data. The Cox model features a greater structure, however,
and is not collapsible (Martinussen and Vansteelandt, 2013). The issue discussed here is relevant
for other methods that are based on the hazard rate. For additive hazard based models, however, the
independence ofX andZ in Section 2.1 is naturally preserved making it another appealing framework
for causal inference like the location-scale model (Strohmaier et al., 2014).
Paradoxically it is well-known that in clinical trials one should not carry out treatment compar-
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isons by conditioning on variables realized post-randomization which may be responsive to treatment
since they may be on the causal pathway to the response of interest (Kalbfleisch and Prentice, 2002).
Treatment comparisons based on sub-groups of individuals defined post-randomization are likewise
termed improper subgroups (Yusuf et al., 1991) and are widely known to yield invalid inferences re-
garding treatment effects because of the benefit of randomization is lost in such comparisons. While
it may be less transparent, the same process of making treatment comparisons based on subgroups
of patients defined post-randomization arises in fitting the Cox model. Indeed in this setting the risk
sets at a given time are defined based on survival status to that time point, a feature clearly responsive
to an effective treatment. This phenomenon is particularly important in settings where interest lies
in studying the time-varying effect of treatment (e.g. Durham et al., 1999) through use of flexible
regression functions.
Causal inference becomes more challenging in settings involving competing risks if cause-specific
analyses are of interest. In a cancer trial, for example, interest may lie in assessing the treatment effect
on tumour progression through a cause-specific proportional hazards model. In patient populations
where the mortality rates are appreciable, the selection effects at any given time arise from the need
to be tumour-free and alive, so the imbalance in confounders arises from both event types. These
challenges are beyond the scope of this article but warrant attention.
The issues presented here relate to comments on the meaning of the hazard rate given in Aalen
et al. (2008) where it is pointed out that despite its deceptively simple definition, clear understanding
of hazard rates is often elusive. These authors provide two interpretations to the hazard rate. The first
is in terms of frailty theory (Chapter 6) and the second is by applying stochastic processes (Wiener
processes and Le´vy processes; Chapters 10 and 11). There is no doubt that the hazard rate is an
important concept for explicating how the past influences the future. However, as we and others have
pointed out, differences between individuals produce selection effects over time which can make it
difficult to draw clear causal conclusions in this framework.
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